Citius Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Citius Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Sep 30, 2013 | $0 | Feb 6, 2014 |
| FY2013 | Sep 30, 2012 | $0 | Feb 6, 2014 |
| FY2012 | Sep 30, 2011 | $0 | Jan 15, 2013 |
| FY2011 | Sep 30, 2010 | $0 | Jan 13, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Sep 30, 2023 | ($32.54M) | Dec 29, 2023 |
| FY2023 | Sep 30, 2022 | ($33.64M) | Dec 29, 2023 |
| FY2022 | Sep 30, 2021 | ($23.05M) | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | ($17.55M) | Dec 15, 2021 |
| FY2020 | Sep 30, 2019 | ($15.56M) | Dec 16, 2020 |
| FY2019 | Sep 30, 2018 | ($12.54M) | Dec 16, 2019 |
| FY2019 | Sep 30, 2017 | ($10.38M) | Dec 16, 2019 |
| FY2018 | Sep 30, 2016 | ($8.30M) | Dec 11, 2018 |
| FY2017 | Sep 30, 2015 | ($2.90M) | Dec 13, 2017 |
| FY2016 | Sep 30, 2014 | ($737.7K) | Dec 23, 2016 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($38.53M) | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | ($42.00M) | Dec 23, 2025 |
| FY2024 | Sep 30, 2023 | ($36.73M) | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | ($33.32M) | Dec 29, 2023 |
| FY2022 | Sep 30, 2021 | ($23.53M) | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | ($17.71M) | Dec 15, 2021 |
| FY2020 | Sep 30, 2019 | ($15.60M) | Dec 16, 2020 |
| FY2019 | Sep 30, 2018 | ($13.79M) | Dec 16, 2019 |
| FY2019 | Sep 30, 2017 | ($9.99M) | Dec 16, 2019 |
| FY2018 | Sep 30, 2016 | ($7.45M) | Dec 11, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $9.16M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $11.91M | Dec 23, 2025 |
| FY2024 | Sep 30, 2023 | $14.82M | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | $17.66M | Dec 29, 2023 |
| FY2022 | Sep 30, 2021 | $12.24M | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | $8.81M | Dec 15, 2021 |
| FY2020 | Sep 30, 2019 | $8.60M | Dec 16, 2020 |
| FY2019 | Sep 30, 2018 | $6.56M | Dec 16, 2019 |
| FY2019 | Sep 30, 2017 | $2.94M | Dec 16, 2019 |
| FY2018 | Sep 30, 2016 | $2.93M | Dec 11, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($26.55M) | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | ($28.20M) | Dec 23, 2025 |
| FY2024 | Sep 30, 2023 | ($29.06M) | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | ($28.36M) | Dec 29, 2023 |
| FY2022 | Sep 30, 2021 | ($24.25M) | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | ($16.93M) | Dec 15, 2021 |
| FY2020 | Sep 30, 2019 | ($12.44M) | Dec 16, 2020 |
| FY2019 | Sep 30, 2018 | ($11.32M) | Dec 16, 2019 |
| FY2019 | Sep 30, 2017 | ($7.97M) | Dec 16, 2019 |
| FY2018 | Sep 30, 2016 | ($5.90M) | Dec 11, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2021 | $6.9K | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | $1.8K | Dec 15, 2021 |
| FY2019 | Sep 30, 2017 | $2.1K | Dec 16, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $130.94M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $116.65M | Dec 23, 2025 |
| FY2024 | Sep 30, 2023 | $103.61M | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | $114.00M | Dec 29, 2023 |
| FY2022 | Sep 30, 2021 | $142.43M | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | $43.77M | Dec 15, 2021 |
| FY2020 | Sep 30, 2019 | $36.75M | Dec 16, 2020 |
| FY2019 | Sep 30, 2018 | $31.05M | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | $24.42M | Dec 11, 2018 |
| FY2017 | Sep 30, 2016 | $21.95M | Dec 13, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $53.41M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $42.55M | Dec 23, 2025 |
| FY2024 | Sep 30, 2023 | $12.18M | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | $10.57M | Dec 29, 2023 |
| FY2022 | Sep 30, 2021 | $9.65M | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | $10.10M | Dec 15, 2021 |
| FY2020 | Sep 30, 2019 | $9.59M | Dec 16, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $67.55M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $70.08M | Dec 23, 2025 |
| FY2024 | Sep 30, 2023 | $90.83M | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | $102.83M | Dec 29, 2023 |
| FY2022 | Sep 30, 2021 | $132.18M | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | $33.67M | Dec 15, 2021 |
| FY2020 | Sep 30, 2019 | $27.15M | Dec 16, 2020 |
| FY2020 | Sep 30, 2018 | $30.64M | Dec 16, 2020 |
| FY2019 | Sep 30, 2017 | $21.95M | Dec 16, 2019 |
| FY2019 | Sep 30, 2016 | $16.77M | Dec 16, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $9.35M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $9.35M | Dec 23, 2025 |
| FY2024 | Sep 30, 2023 | $9.35M | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | $9.35M | Dec 29, 2023 |
| FY2022 | Sep 30, 2021 | $9.35M | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | $9.35M | Dec 15, 2021 |
| FY2020 | Sep 30, 2019 | $9.35M | Dec 16, 2020 |
| FY2019 | Sep 30, 2018 | $1.59M | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | $1.59M | Dec 11, 2018 |
| FY2017 | Sep 30, 2016 | $1.59M | Dec 13, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($238.80M) | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | ($201.37M) | Dec 23, 2025 |
| FY2024 | Sep 30, 2023 | ($162.23M) | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | ($129.69M) | Dec 29, 2023 |
| FY2022 | Sep 30, 2021 | ($96.05M) | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | ($70.59M) | Dec 15, 2021 |
| FY2020 | Sep 30, 2019 | ($53.05M) | Dec 16, 2020 |
| FY2019 | Sep 30, 2018 | ($40.26M) | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | ($27.72M) | Dec 11, 2018 |
| FY2017 | Sep 30, 2016 | ($17.34M) | Dec 13, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $4.25M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $3.25M | Dec 23, 2025 |
| FY2024 | Sep 30, 2023 | $26.48M | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | $41.71M | Dec 29, 2023 |
| FY2022 | Sep 30, 2021 | $70.07M | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | $13.86M | Dec 15, 2021 |
| FY2021 | Sep 30, 2019 | $7.89M | Dec 15, 2021 |
| FY2020 | Sep 30, 2018 | $9.18M | Dec 16, 2020 |
| FY2019 | Sep 30, 2017 | $3.20M | Dec 16, 2019 |
| FY2019 | Sep 30, 2016 | $294.4K | Dec 16, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (3) | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | (5) | Dec 23, 2025 |
| FY2024 | Sep 30, 2023 | (5) | Dec 27, 2024 |
| FY2022 | Sep 30, 2022 | 0 | Dec 22, 2022 |
| FY2022 | Sep 30, 2021 | 0 | Dec 22, 2022 |
| FY2013 | Sep 30, 2013 | 0 | Feb 6, 2014 |
| FY2013 | Sep 30, 2012 | 0 | Feb 6, 2014 |
| FY2012 | Sep 30, 2011 | 0 | Jan 15, 2013 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (3) | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | (5) | Dec 23, 2025 |
| FY2024 | Sep 30, 2023 | (5) | Dec 27, 2024 |
| FY2022 | Sep 30, 2022 | 0 | Dec 22, 2022 |
| FY2022 | Sep 30, 2021 | 0 | Dec 22, 2022 |
| FY2013 | Sep 30, 2013 | 0 | Feb 6, 2014 |
| FY2013 | Sep 30, 2012 | 0 | Feb 6, 2014 |
| FY2012 | Sep 30, 2011 | 0 | Jan 15, 2013 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 18.07M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | 7.25M | Dec 23, 2025 |
| FY2024 | Sep 30, 2023 | 6.35M | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | 146.21M | Dec 29, 2023 |
| FY2022 | Sep 30, 2021 | 145.98M | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | 55.58M | Dec 15, 2021 |
| FY2020 | Sep 30, 2019 | 28.93M | Dec 16, 2020 |
| FY2019 | Sep 30, 2018 | 16.20M | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | 8.35M | Dec 11, 2018 |
| FY2017 | Sep 30, 2016 | 4.88M | Dec 13, 2017 |